<DOC>
	<DOCNO>NCT00023998</DOCNO>
	<brief_summary>Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell kill without harm normal cell . Combining monoclonal antibody therapy chemotherapy may kill tumor cell . Phase II trial study effectiveness chemotherapy without trastuzumab treat patient metastatic osteosarcoma</brief_summary>
	<brief_title>Chemotherapy With Without Trastuzumab Treating Patients With Metastatic Osteosarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine feasibility safety trastuzumab ( Herceptin ) chemotherapy patient HER2-overexpressing ( 2+ level expression ) metastatic osteosarcoma . II . Determine response rate 3-year event-free survival patient treat regimen . III . Determine cardiac toxicity late effect regimen patient . IV . Determine response rate 3-year event-free survival poor-risk patient HER2-negative tumor treat chemotherapy without addition trastuzumab . OUTLINE : This multicenter study . Patients stratify accord tumor HER2 status ( positive v negative ) . Patients receive induction therapy comprise doxorubicin IV 20 minute follow cisplatin IV 4 hour day 1 2 week 1 6 , methotrexate IV 4 hour day 1 week 4 , 5 , 9 , 10 . Patients also receive leucovorin calcium IV orally every 6 hour begin 24 hour methotrexate dose continue least 10 dos methotrexate level sufficiently decrease . Within 24-36 hour completion induction therapy , patient receive filgrastim ( G-CSF ) daily blood count recover . Patients undergo resection remain primary tumor and/or metastatic lesion week 11 . Patients unable undergo resection receive radiotherapy week 11 17 . Patients receive post-induction therapy comprise doxorubicin IV 20 minute day 1 2 week 17 , 25 , 29 ; cisplatin IV 4 hour day 1 2 week 17 25 ; methotrexate IV 4 hour day 1 week 16 , 20 , 24 , 28 , 32 , 33 ; etoposide IV 1 hour day 1-5 week 13 , 21 , 34 ; ifosfamide IV 4 hour day 1-5 week 13 , 21 , 29 , 34 . Patients also receive leucovorin calcium G-CSF induction therapy . Patients whose tumor find express HER2 ( 2+ level expression ) also receive trastuzumab IV 30-90 minute week total 34 week addition chemotherapy regimen . Patients follow monthly 1 year , every 2 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 80 patient ( 40 patient per stratum ) accrue study within 2.5 year .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Histologically confirm highgrade osteosarcoma Metastatic Newly diagnose No osteosarcoma arise area Paget 's disease radiotherapyinduced sarcoma Presenting least 1 follow : Bone metastases without lung metastasis Bilateral lung metastasis ( number nodule ) Unilateral lung metastasis least 4 nodule Planned resection either primary site metastatic site disease completion induction therapy Must currently enrol tumor biology study COGP9851 Performance status ECOG 02 Performance status Karnofsky 50100 % ( age 10 ) Performance status Lansky 50100 % ( age 10 ) Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Bilirubin ≤ 1.5 time normal SGPT ≤ 3 time normal Creatinine ≤ 1.5 time normal Creatinine clearance glomerular filtration rate ≥ 70 mL/min Shortening fraction ≥ 28 % echocardiogram Ejection fraction ≥ 50 % echocardiogram MUGA No history pericarditis , myocarditis , symptomatic arrhythmia , conduction disturbance Normal organ function HIV negative Not pregnant nursing Fertile patient must use effective contraception No prior chemotherapy No prior radiotherapy See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>